




RealRate

PHARMACEUTICAL 2022

Landos Biopharma Inc
Rank 182 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Landos Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Landos Biopharma Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Landos Biopharma Inc is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 324%, being 49% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	92,146
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,611
Liabilities, Non-Current	0
Other Assets	26
Other Compr. Net Income	159
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	18,000
Property and Equipment	707
Research and Development	41,564
Selling, General and Administrative Expense	15,252

Output Variable	Value in 1000 USD
Assets	92,879
Liabilities	16,611
Expenses	56,816
Revenues	18,000
Stockholders Equity	76,268
Net Income	-38,816
Comprehensive Net Income	-38,736
BaseVar	92,232
ECR before LimitedLiability	233%
Economic Capital Ratio	324%